---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-049815"
form_type: "8-K/A"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T03:59:47.302555+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NAYA Biosciences completes merger with Legacy NAYA; stock and debt exchange detailed

## Summary
- Each Legacy NAYA share exchanged for 118,148 NAYA common shares and 30,375 Series C-1 Preferred shares (convertible only after stockholder approval).
- $8.58M Legacy NAYA debt converted into 669,508 common shares and 8,576 Series C-2 Preferred; remaining $3.93M exchanged for new 7% Senior Secured Convertible Debenture due Dec 2025.
- Dr. Daniel Teper appointed President; CEO Steven Shum and CFO Andrea Goren remain; Teper and Lyn Falconio join board of directors.
- Legacy NAYA audited results: no revenue for 2022 or 2023; net loss $3.28M in 2023, $9.5M in 2022; going concern noted.
- Stockholder meeting required to ratify merger, increase authorized shares to 100M, and approve reverse stock split (1:2 to 1:20).

## SEC filing metadata
- accession: 0001493152-24-049815
- form_type: 8-K/A
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315224049815/0001493152-24-049815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315224049815/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-049815
- JSON: https://secwatch.observer/filing/0001493152-24-049815.json
- Plain text: https://secwatch.observer/filing/0001493152-24-049815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.